Compounds › Repair and tissue

Cartalax

Short bioregulator studied in cartilage

Not approvedRepair and tissue

AI-generated illustration. Not data, and not an image from a study.

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

Summary

Short peptide studied in cartilage cells and in cellular models of aging. There is a wide gap between the published laboratory research and the injectable schedules that circulate in the communities — the page keeps the two apart.

Quick reference

Route: Injectable, from a reconstituted vial.
Evidence base: Research in cartilage cells and cellular models of aging.
Status: Not approved. Wide gap between what is published and what circulates.

Cartalax protocol formats

Phase	Daily amount	U-100 units	Volume	Reported frequency
Weeks 1-2	2 mg	30 units	0.30 mL	1×/day
Weeks 3-4	3 mg	45 units	0.45 mL	1×/day
Weeks 5-8	4 mg	60 units	0.60 mL	1×/day
Weeks 9-12	5 mg	75 units	0.75 mL	1×/day

Cartalax protocol formats

Research model	Cartalax exposure	Measured outcome
Human mesenchymal stem cells during replicative aging	200 ng/mL in cell culture	SOX9, aggrecan, type II collagen, and COMP expression
Cultured rat chondrocytes	200 ng/mL in cell culture	Number and proliferation of chondrocytes
Aging human stem-cell cultures	Experimental cell exposure	Changes in selected gene-expression pathways
Aging skin fibroblast cultures	Experimental cell exposure	Proliferation, matrix-remodeling, and apoptosis markers

Cartalax Capsules vs Injection

Feature	Oral products	Injectable research vials
Typical form	Capsule, tablet, or lingual product	Lyophilized powder in a vial
Common label context	Short commercial courses such as 10–30 days	Online community schedules, often using a 20 mg vial
Active amount	May not equal the full capsule weight	Usually listed as total milligrams of research material
Human bioavailability	Not clearly established for pure AED	Not established in controlled Cartalax studies
Validated human protocol	No widely accepted clinical protocol	No validated injectable protocol

Cartalax vs BPC-157

Feature	Cartalax	BPC-157
Peptide size	Three amino acids	Fifteen amino acids
Common name	AED or T-31	Body Protection Compound-157
Main research focus	Cartilage-cell differentiation and gene-expression markers	Injury, tissue-healing, blood-vessel, and gastrointestinal models
Most direct evidence	Cell-culture studies	Mostly animal and laboratory studies
Human injectable dose	Not established	Not established as an approved musculoskeletal protocol
FDA approval	Not FDA-approved	Not FDA-approved
Evidence for combining them	No controlled study supports a Cartalax and BPC-157 stack	No controlled study supports a Cartalax and BPC-157 stack

Sigumir vs Cartalax

Feature	Cartalax	Sigumir
Main identity	Synthetic AED tripeptide	Broader cartilage-derived peptide complex in commercial product descriptions
Defined sequence	Ala-Glu-Asp	May contain a mixture rather than one defined tripeptide
Research-vial format	Often sold as pure lyophilized AED	More often linked with oral bioregulator products
Are they interchangeable?	No	No

Cartalax Cycle Chart

Weeks	Daily amount	Days	Phase total	Running total
1–2	2 mg	14	28 mg	28 mg
3–4	3 mg	14	42 mg	70 mg
5–8	4 mg	28	112 mg	182 mg
9–12	5 mg	28	140 mg	322 mg

Cartalax Cycle Calendar

Cycle day	Week	Community schedule event	Daily amount
Day 1	Week 1	First phase begins	2 mg
Day 15	Week 3	Second phase begins	3 mg
Day 29	Week 5	Third phase begins	4 mg
Day 57	Week 9	Fourth phase begins	5 mg
Day 84	End of week 12	Final day of the main schedule	5 mg
Day 85	Week 13	Calculated extension begins, if included	5 mg
Day 112	End of week 16	Final day of the extended schedule	5 mg

Cartalax 8-Week Cycle

Weeks	Daily amount	Weekly amount	Phase total
1–2	2 mg	14 mg	28 mg
3–4	3 mg	21 mg	42 mg
5–8	4 mg	28 mg	112 mg

Cartalax 12-Week Cycle

Weeks	Daily amount	Weekly amount	Phase total
1–2	2 mg	14 mg	28 mg
3–4	3 mg	21 mg	42 mg
5–8	4 mg	28 mg	112 mg
9–12	5 mg	35 mg	140 mg

Cartalax 16-Week Cycle

Weeks	Daily amount	Weekly amount	Phase total
1–2	2 mg	14 mg	28 mg
3–4	3 mg	21 mg	42 mg
5–8	4 mg	28 mg	112 mg
9–12	5 mg	35 mg	140 mg
13–16	5 mg	35 mg	140 mg

Cartalax Cycle Length Comparison

Cycle	Total exposure	Difference	Evidence status
8 weeks	182 mg	Stops after the 4 mg phase	Community-reported
12 weeks	322 mg	Adds four weeks at 5 mg daily	Community-reported
16 weeks	462 mg	Extends the 5 mg phase for four more weeks	Calculated community extension
10 mg for 20 days	200 mg	Uses a higher fixed amount for a shorter period	Commercial and community claim

Cartalax Cycle Breaks, Pauses, and Schedule Changes

Question	Current answer
Is a break required after eight weeks?	No published study provides a required break.
Can another cycle begin right away?	Human safety data do not support a clear answer.
Does Cartalax build up over time?	Human pharmacokinetics and tissue accumulation are unknown.
Is cycling better than continuous exposure?	The two approaches have not been compared.
Does a longer break reset tolerance?	Tolerance has not been established for Cartalax.

Cartalax Cycle Vial Math

Cycle	Phase calculation	Total	Vials required
8 weeks	28 mg + 42 mg + 112 mg	182 mg	10 vials
12 weeks	182 mg + 140 mg	322 mg	17 vials
16 weeks	322 mg + 140 mg	462 mg	24 vials
10 mg for 20 days	10 mg × 20 days	200 mg	10 vials

Cartalax Cycle Vial Math

Daily amount	Mathematical duration	Full daily amounts	Amount remaining
2 mg	10 days	10	0 mg
3 mg	About 6.7 days	6	2 mg
4 mg	5 days	5	0 mg
5 mg	4 days	4	0 mg
10 mg	2 days	2	0 mg

Cartalax Cycle Vial Math

Cycle	Minimum from total milligrams	Phase totals rounded separately	Difference
8 weeks	10 vials	11 vials	1 vial
12 weeks	17 vials	18 vials	1 vial
16 weeks	24 vials	25 vials	1 vial

Cartalax Cycle Tracking and Supply Planning

Date	Cycle day	Phase	Planned amount	Vial number	Cumulative total	Notes
[Date]	[Day]	[Weeks 1–2, 3–4, 5–8, or 9–12]	[Amount]	[Vial]	[Running total]	[Pause, loss, or schedule change]
[Date]	[Day]	[Phase]	[Amount]	[Vial]	[Running total]	[Notes]
[Date]	[Day]	[Phase]	[Amount]	[Vial]	[Running total]	[Notes]

Storage and handling

The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.

Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
Cloudy solution, with particles or a color change: discard. There is no recovery.

Lab tests and monitoring

This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.

Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.

Evidence limits

What these numbers are and what they are not. The values above were preserved exactly as they appear in the source, without reinterpretation. What the source describes as community practice is marked as such in the tables; what came from a published trial is too. A dose repeated by many people does not become a validated dose by repetition.

← Back to all compounds